Worse Case, page-37

Barriers and hurdles for PAR will be continual until approvals and commercialisation are archived. In relation to the height of the hurdles this is only the beginning and in regards to the FDA and Big Pharma just wait until the games really start. As we are all aware the revenue potential for PAR is astronomical a factor that is well and truly on the watch list of many a big pharma. The simple questions are does one believe in the product/s under development and the data to date and does one believe the BOD and management have the skills and know how to 'successfully' traverse the mine field that is FDA approval and the political games and influence that big pharma will play and yield. On the first point i am a believer on the second the jury for me is still out. Will i be around at the end ? Well having been in since 2017 you bet! GLTAH